Insulin resistance in patients with cancer: a systematic review and meta-analysis

References

• Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578.
   PubMed Web of Science ®Google Scholar
• Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30(3):561–567.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755–765.
   PubMed Web of Science ®Google Scholar
• Campbell PT, Jacobs EJ, Newton CC, et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–1844.
   PubMed Web of Science ®Google Scholar
• Zhang AMY, Magrill J, de Winter TJJ, et al. Endogenous hyperinsulinemia contributes to pancreatic cancer development. Cell Metab. 2019;30(3):403–404.
   PubMed Web of Science ®Google Scholar
• Zhong W, Mao Y. Daily insulin dose and cancer risk among patients with type 1 diabetes. JAMA Oncol. 2022;8(9):1356.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42–51.
   PubMed Web of Science ®Google Scholar
• Tam CS, Xie W, Johnson WD, et al. Defining insulin resistance from hyperinsulinemic–euglycemic clamps. Diabetes Care. 2012;35(7):1605–1610.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl. 2):S157–S163.
   PubMed Web of Science ®Google Scholar
• Hansen SL, Svendsen PF, Jeppesen JF, et al. Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(5):1841–1854.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42.
   PubMed Web of Science ®Google Scholar
• Bressler P, Bailey SR, Matsuda M, et al. Insulin resistance and coronary artery disease. Diabetologia. 1996;39(11):1345–1350.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Haddaway NR, Grainger MJ, Gray CT. Citationchaser: a tool for transparent and efficient forward and backward citation chasing in systematic searching. Res Synth Methods. 2022;13(4):533–545.
   PubMed Web of Science ®Google Scholar
• Thomas J, Graziosi S, Brunton J, et al. EPPI-Reviewer: advanced software for systematic reviews, maps and evidence synthesis. https://eppi.ioe.ac.uk/EPPIReviewer-Web. 2022.
   Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–E223.
   PubMed Web of Science ®Google Scholar
• Byerley LO, Heber D, Bergman RN, et al. Insulin action and metabolism in patients with head and neck cancer. Cancer. 1991;67(11):2900–2906.
   PubMed Web of Science ®Google Scholar
• Pisters PWT, Cersosimo E, Rogatko A, et al. Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery. 1992;111(3):301–310.
   PubMed Web of Science ®Google Scholar
• Cersosimo E, Pisters PWT, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67(2):486–493.
   PubMed Web of Science ®Google Scholar
• Minn H, Lindholm P, Nuutila P, et al. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer. 1994;73(5):1490–1498.
   PubMed Web of Science ®Google Scholar
• Tayek JA. Reduced non-oxidative glucose utilization in cancer patients is associated with a low triiodothyronine concentration. J Am Coll Nutr. 1995;14(4):341–348.
   PubMed Web of Science ®Google Scholar
• Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr. 2012;31(5):765–773.
   PubMed Web of Science ®Google Scholar
• Cersosimo E, Pisters PW, Pesola G, et al. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. 1991;109:459–467.
   PubMed Web of Science ®Google Scholar
• Copeland GP, Leinster SJ, Davis JC, et al. Insulin resistance in patients with colorectal cancer. Br J Surg. 1987;74(11):1031–1035.
   PubMed Web of Science ®Google Scholar
• de Melo TG, Souza AL, Ficher E, et al. Reduced insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH. Endocr Res. 2018;43(2):73–79.
   PubMed Web of Science ®Google Scholar
• Dodesini AR, Benedini S, Terruzzi I, et al. Protein, glucose and lipid metabolism in the cancer cachexia: a preliminary report. Acta Oncol. 2007;46(1):118–120.
   PubMed Web of Science ®Google Scholar
• Heslin MJ, Newman E, Wolf RF, et al. Effect of systemic hyperinsulinemia in cancer patients. Cancer Res. 1992;52:3845–3850.
   PubMed Web of Science ®Google Scholar
• Makino T, Noguchi Y, Yoshikawa T, et al. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br J Surg. 1998;85(12):1658–1662.
   PubMed Web of Science ®Google Scholar
• McCall JL, Tuckey JA, Parry BR. Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br J Surg. 1992;79(12):1361–1363.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Noguchi Y, Doi C, et al. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition. 2001;17(7–8):590–593.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Noguchi Y, Doi C, et al. Insulin resistance was connected with the alterations of substrate utilization in patients with cancer. Cancer Lett. 1999;141(1–2):93–98.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Noguchi Y, Matsumoto A. Effects of tumor removal and body weight loss on insulin resistance in patients with cancer. Surgery. 1994;116(1):62–66.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Chichester, UK: Wiley; 2019. p. 1–694.
   Google Scholar
• Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions [Internet]; 2019 [cited 2022 Jul 16]. p. 241–284. Available from: 10.1002/9781119536604.ch10
   Google Scholar
• Sylow L, Tokarz VL, Richter EA, et al. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 2021;33(4):758–780.
   PubMed Web of Science ®Google Scholar
• Sylow L, Grand MK, von Heymann A, et al. Incidence of new-onset type 2 diabetes after cancer: a Danish Cohort Study. Diabetes Care. 2022;45(6):e105–e106.
   PubMed Web of Science ®Google Scholar
• Hwangbo Y, Kang D, Kang M, et al. Incidence of diabetes after cancer development: a Korean National Cohort Study. JAMA Oncol. 2018;4(8):1099–1105.
   PubMed Web of Science ®Google Scholar
• Park J, Morley TS, Kim M, et al. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–465.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207–221.
   PubMed Web of Science ®Google Scholar
• Boudoulas KD, Triposkiadis F, Gumina R, et al. Cardiovascular disease, cancer, and multimorbidity interactions: clinical implications. Cardiology. 2022;147(2):196–206.
   PubMed Web of Science ®Google Scholar
• Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–166.
   PubMed Web of Science ®Google Scholar
• Honors MA, Kinzig KP. The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3(1):5–11.
   PubMed Web of Science ®Google Scholar
• Sylow L, Vind BF, Kruse R, et al. Circulating follistatin and activin A and their regulation by insulin in obesity and type 2 diabetes. J Clin Endocrinol Metab. 2020;105(5):dgaa090.
   PubMed Web of Science ®Google Scholar
• Han X, Raun SH, Carlsson M, et al. Cancer causes metabolic perturbations associated with reduced insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular perfusion. Metabolism. 2020;105:154169.
   PubMed Web of Science ®Google Scholar
• Raun SH, Knudsen JR, Han X, et al. Cancer causes dysfunctional insulin signaling and glucose transport in a muscle-type-specific manner. FASEB J. 2022;36(3):e22211.
   PubMed Web of Science ®Google Scholar
• Ariaans G, de Jong S, Gietema JA, et al. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat Rev. 2015;41(4):376–384.
   PubMed Web of Science ®Google Scholar
• Hwangbo Y, Lee EK. Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metab. 2017;32(1):23–29.
   Web of Science ®Google Scholar
• Perez A, Jansen-Chaparro S, Saigi I, et al. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9–20.
   PubMed Web of Science ®Google Scholar
• Schultz H, Pedersen-Bjergaard U, Jensen AK, et al. The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression. Clin Transl Radiat Oncol. 2018;11:19–25.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–498.
   PubMed Web of Science ®Google Scholar
• Raun SH, Buch-Larsen K, Schwarz P, et al. Exercise—a panacea of metabolic dysregulation in cancer: physiological and molecular insights. Int J Mol Sci. 2021;22(7):3469.
   PubMed Web of Science ®Google Scholar
• Sylow L, Richter EA. Current advances in our understanding of exercise as medicine in metabolic disease. Curr Opin Physiol. 2019;12:12–19.
   Web of Science ®Google Scholar
• Schmitz KH, Campbell AM, Stuiver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69(6):468–484.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Lindström J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2005;54(1):158–165.
   PubMed Web of Science ®Google Scholar
• Granger CL, McDonald CF, Irving L, et al. Low physical activity levels and functional decline in individuals with lung cancer. Lung Cancer. 2014;83(2):292–299.
   PubMed Web of Science ®Google Scholar